UCB buys its way to epilep­sy show­down with Jazz with $1.9B Zo­genix ac­qui­si­tion

4 years ago
Deals

GSK R&D chief Hal Bar­ron jumps ship to run a $3B biotech start­up, Tony Wood tapped to re­place him

4 years ago
People

What kind of biotech start­up wins a $3B syn­di­cate, woos a gallery of mar­quee sci­en­tists and re­cruits GSK's Hal Bar­ron ...

4 years ago
Deals
Cell/Gene Tx

British bil­lion­aire Mike Platt hops on board a Lon­don start­up look­ing at drug dis­cov­ery from a dif­fer­ent an­gle

4 years ago
Financing
Startups

Emer­gent TV ads book­end its tu­mul­tuous year. Can mil­i­tary, Nar­can work help re­hab its brand?

4 years ago
Pharma
Marketing

EQRx adds ar­mor to its dis­count check­point in­hibitor sub­mis­sion, nail­ing sur­vival mark in key study

4 years ago
R&D

With its lead CAR-T flash­ing some PhI da­ta, Ar­cel­lx read­ies a jump to Nas­daq

4 years ago
Financing

Q&A: Bio­Marin com­mer­cial chief Jeff Ajer gears up for biggest drug launch to date — with an­oth­er wait­ing in the ...

4 years ago
Pharma
Marketing

Mar­ket­ingRx roundup: Aduhelm can’t get trac­tion with docs; Pfiz­er press­es vac­cine ef­fort dur­ing NFL play­offs

4 years ago
Pharma
Marketing

Ogilvy Health’s new chief cre­ative of­fi­cer Adam Hes­sel con­tem­plates cre­ative pros and cons of Covid

4 years ago
Pharma
Marketing

En­do reach­es opi­oid set­tle­ment in Flori­da; De­moc­rats call on CMS to low­er pre­mi­ums fol­low­ing Aduhelm price cut

4 years ago
News Briefing

UK up­start rais­es $100M in bid to dig­i­tize and stan­dard­ize cell and gene ther­a­py man­u­fac­tur­ing

4 years ago
Cell/Gene Tx
Manufacturing

Se­ma4 shells out $623M to scoop up a lead­ing di­ag­nos­tics play­er and its trove of da­ta

4 years ago
Deals

Hal Bar­ron keeps 23andMe close on GSK's side to find more genes the R&D team can go af­ter

4 years ago
Deals

Bil­lion­aires Chamath Pal­i­hapi­tiya and Pablo Legor­re­ta hatch an $825M SPAC for cell ther­a­py biotech

4 years ago
Financing

No stranger to head­winds, blue­bird runs in­to two PDU­FA de­lays un­re­lat­ed to new safe­ty is­sues

4 years ago
R&D
FDA+

With few re­main­ing un­ap­proved drugs, re­searchers tell FDA its Un­ap­proved Drugs Ini­tia­tive is no longer ef­fec­tive

4 years ago
FDA+

CBO: Medicare ne­go­ti­a­tions will ham­per drug de­vel­op­ment more than pre­vi­ous­ly thought

4 years ago
Pharma
FDA+

FDA or­ders DMD tri­al halt, rais­ing ques­tions about a whole class of promis­ing drugs

4 years ago
R&D
Cell/Gene Tx

An­ti­body leg­end Till­man Gern­gross in­tro­duces his lat­est com­pa­ny, with an In­novent deal al­ready lined up

4 years ago
Startups
Deals

Covid-19 roundup: Pfiz­er ex­pands in­to France; Omi­cron-spe­cif­ic ver­sion of Mod­er­na's boost­er com­ing soon 

4 years ago
Coronavirus

Tiny biotech ham­mered as lead drug fails a key PhII study

4 years ago
R&D

Ready for an M&A fight? Af­ter GSK shunned $68B of­fer, Unilever says it's still in hunt for con­sumer health JV

4 years ago
Deals
Pharma

Mar­tin Shkre­li re­ceives life­time in­dus­try ban, forced to re­turn al­most $65M in prof­its af­ter an­ti­com­pet­i­tive scheme

4 years ago
People
Pharma
First page Previous page 597598599600601602603 Next page Last page
A service from the Financial Times